Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- WestBond's Stellar Financial Growth and Market Opportunities
- Workday Financial Performance Shows Strong Growth in Q2 2026
- Tryst Hospitality to Launch The Tryst Ipanema in Brazil, 2026
- Upcoming Financial Release Details from American Outdoor Brands
- Unlocking Potential: Revenue Growth Through Storytelling
- The Hanover Insurance Group to Showcase Leadership Insights
- The Home Depot Announces $2.30 Quarterly Dividend Payment
- WinVest Acquisition Corp. Changes Special Meeting Date for Stockholders
- EOG Resources Prepares for Major Energy Conference Presentation
- Dillard’s, Inc. Declares New Cash Dividend for Shareholders
- Miller Industries Engages Investors at the Midwest IDEAS Event
- Cycurion Inc. Achieves Nasdaq Compliance, Strengthens Market Position
- Darden Restaurants Plans First Quarter Earnings Conference Call
- Itron Welcomes Scott Drury to the Board of Directors
- Gap Inc. Engages in Goldman Sachs Global Retailing Conference
- Atlanticus Holds Strong with Recent Preferred Stock Dividend
- Extra Space Storage Inc. Declares Robust Q3 2025 Dividend
- Quanex Building Products Prepares for Third Quarter Earnings Call
- Jazz Pharmaceuticals Engages at Upcoming Healthcare Event
- Burlington Stores Welcomes Michael Skirvin to Leadership Team
- Advancements in Tissue Engineering and Space Research with SpaceX
- Talkspace: Innovating Mental Health Solutions for All
- Bubblr Inc. Responds to Promotional Activity Allegations
- Health Catalyst to Showcase Innovations at Key Investor Events
- Highwoods Properties Expands with Legacy Union Parking Garage
- AVITA Medical's Upcoming Investor Conferences Highlight Growth
- Critical Market Insights on E-Mini S&P 500 Dynamics Ahead
- UTime Ltd. Faces Compliance Challenges with Nasdaq Standards
- Sarepta Therapeutics Faces Class Action Lawsuit Over ELEVIDYS Safety
- Fast Food Stocks Rising: Key Players in the Evolving Market
- Fortinet, Inc. Faces Investigation Over Securities Fraud Claims
- LifeVantage Corporation's Financial Results Announcement Insights
- LifeVantage Scheduled to Share Q4 and Full Fiscal Year Results
- Methode Electronics' Financial Outlook Set for Q1 FY2026
- Cullinan Therapeutics Engages in Key Investor Conversations
- Talkspace Prepares for an Exciting Investor Conference Event
- Upcoming Terns Pharmaceuticals Webinar on TERN-701 Clinical Trial Insights
- Terns Pharmaceuticals Hosting a Key Webinar on TERN-701
- Explore Red Violet's Innovative Solutions at Upcoming Conference
- AVITA Medical to Showcase Innovations at Upcoming Investor Events
- Methode Electronics Prepares for Upcoming Quarterly Earnings Call
- Zumiez Inc. Set to Reveal Second Quarter Earnings Soon
- Madrigal Pharmaceuticals Rewards New Employees with Equity Awards
- GCT Semiconductor Holding, Inc. Prepares for Upcoming Conferences
- LPL Financial July Activity Report Highlights Increased Assets
- Red Violet, Inc. Showcases Innovations at Investor Conference
- Zumiez Inc. Set to Announce Fiscal 2025 Q2 Financials Soon
- Health Catalyst's Upcoming Investor Conference Participation
- Oculis' Q2 2025 Results Showcase Clinical Advancements
- Charter Communications Legal Action: Important Investor Alert